REG - Diaceutics PLC - Purchase and Sale of Shares and PDMR Shareholdings

DiaceuticsAnnouncement

06/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230606:nRSF7228Ba&default-theme=true

RNS Number : 7228B  Diaceutics PLC  06 June 2023

 

 

6 June 2023

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

Purchase and Sale of Shares and PDMR Shareholdings

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
technology and solutions provider to the pharmaceutical industry announces the
following Director and PDMR share dealing.

 

On 5 June 2023, Nick Roberts, CFO of Diaceutics, purchased 21,742 ordinary
shares of £0.002 each in the Company ("Ordinary Shares") at a price of 91.75
pence per Ordinary Share. As a result of the purchase, Nick's shareholding is
62,576 Ordinary Shares, representing approximately 0.07% of the Company's
issued share capital.

 

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Nick Adams

 Kate Hanshaw

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny

 Matthew Young

 Kinvara Verdon

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation of
their precision medicines, enabled by the proprietary DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Nick Roberts
 2   Reason for notification
 a.  Position/Status                                              CFO
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Purchase
 c.  Price(s) and volume(s)                                                    Share purchase:
                                                                               Price(s)     Volume(s)
     91.75p                                                                    21,742

 d.  Date of the transaction                                      5 June 2023
 e.  Place of the transaction                                     AIM Market of the London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFLIRRIEIIV